Menu
  • Join
  • Login
  • Contact
 

Search abstracts


The impact of a change in tacrolimus monitoring immunoassay techniques on clinical decision making and patient outcomes

  • At: 2009 FIP Congress in Istanbul (Turkey)
  • Type: Poster
  • By: CAVANAUGH, Teresa (James L Winkle College of Pharmacy, Cincinnati, United States of America)
  • Co-author(s): Parrish, Nicholas (The University Hospital Department of Pharmacy, CINCINNATI, United States of America)
    Neff, Guy (University of Cincinnati College of Medicine, CINCINNATI, United States of America)
    Rudich, Steven (The University Hospital Department of Surgery, CINCINNATI, United States of America)
    Martin-Boone, Jill (James L Winkle College of Pharmacy, CINCINNATI, United States of America)
  • Abstract:

    Background: Tacrolimus (TAC) is an immunosuppressive agent that undergoes extensive therapeutic drug monitoring. Our program evaluated TAC levels using fluorescence polarization immunoassay (FPIA) technology; however, the lab changed assay methodology to the cloned enzyme donation immunoassay (CEDIA). The purpose of this study was to evaluate..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses